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Objectives: Tumor necrosis factor-a (TNF-a) plays roles in the development of
obesity, insulin resistance, and possibility of Type 2 diabetes mellitus (T2DM).
The objective of the current study was to evaluate the association of TNF-a
promoter308 G/A polymorphism with T2DM.
Methods: In all, 1038 patients with T2DM and 1023 normoglycemic controls
were included in this study. All participants were genotyped using the poly-
merase chain reaction-restriction fragment length polymorphism method.
Genotypic and allelic frequencies were then analyzed in each group. Serum
lipids, fasting glucose, fasting serum insulin, homeostatic model assessment of
insulin resistance, and hemoglogin A1c levels were determined by conventional
methods.
Results: The allelic frequency of the A allele was significantly different be-
tween case and control participants (p Z 0.006). Genotypes GA and AA were
found to be significantly associated with 2.24- and 3.18-fold increased risk for
T2DM, respectively. Similarly, the dominant model of -308 G/A polymorphism
was found to have a higher risk for T2DM (odds ratio Z 2.34, p Z 0.001). In-
dividuals with T2DM carrying the GA þ AA genotypes of -308 G/A variation had
significantly lower fasting plasma insulin than those carrying GG genotype.
Conclusion: Our findings revealed that there is an association between the TNF-
a promoter -308 G/A polymorphism and T2DM in this population.yari-s@medilam.ac.ir (S. Bakhtiyari).
ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
) which permits unrestricted non-commercial use, distribution, and reproduction in any
operly cited.
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
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Type 2 diabetes mellitus (T2DM) is a chronic
metabolic disorder in which prevalence has been
increasing steadily all over the world [1]. Currently, 366
million people have diabetes worldwide, and the number
is predicted to reach 552 million by 2030 [2]. T2DM is
characterized by peripheral insulin resistance in the
liver, skeletal muscle, and adipose tissues, as well as
impaired insulin secretion from the pancreatic beta cells
[3]. Evidence has been presented that Type 2 diabetes
mellitus (T2DM) drives from the coexistence of genetic
and environmental factors [4,5]. However, the molecular
mechanisms underlying T2DM are poorly understood.
The role of tumor necrosis factor (TNF)-a in the
pathogenesis of T2DM has been investigated in several
studies. The TNF-a gene is located within the HLA III
region in chromosome 6p21, and involved in inflam-
matory responses. This gene encodes a potent cytokine
that has been implicated as an important factor in
obesity-associated insulin resistance and pathogenesis of
T2DM [6e8]. There were studies focused on TNF-a
-308 G/A polymorphism (rs1800629), which lead to a
higher rate of TNF-a gene transcription than that of
wild-type in vitro expression studies [9]. It is reported
that -308 G/A polymorphism associates with either
increased or decreased insulin resistance in patients with
T2DM and patients without diabetes [10e15]. A recent
meta-analysis reported no relationship of this poly-
morphism with risk for T2DM [16]. Because of
controversial reports from several populations, there is
still no definitive evidence of the association between
this variation and risk for T2DM [9]. Hence, further
studies in different population are needed to clarify the
precise role of TNF-a -308 G/A polymorphism in sus-
ceptibility to T2DM.
To our knowledge, because the relationship between
-308 G/A polymorphism of TNF-a and T2DM in the
Kurdish ethnic group of Iran have not yet been addressed
and because of controversial results from other pop-
ulations, we aimed to explore the possible association
between this polymorphism and T2DM and its metabolic
quantitative traits in a sample of the Iranian Kurdish
ethnic group. We examined the allele and genotype
frequencies of above polymorphism in patients with and
without T2DM, and detected their effects on anthropo-
metric, diabetes, and obesity-related parameters.2. Material and methods
2.1. Participants and protocols
The study population included 1038 Iranian unrelated
patients with T2DM (males/females: 502/536; age:
54.98  1.01 years) and 1023 Iranian unrelated healthy
controls (males/females: 493/530; age: 53.3  9.7
years). All patients originated from Ilam andKermanshah provinces situated in the west of Iran, and
belonged to the Kurdish ethnic group. Patients with
diabetes and healthy controls were distinguished based
on their glycemic status, which was defined according to
World Health Organization 1997 criteria [17]. The
control group only contained individuals with a normal
fasting glucose level and negative family history of
T2DM among first-degree relatives. The written
informed consent was obtained from all participants
prior to enrollment in the study.
Screening included standardized questionnaires for
personal data and clinical measurements such as age,
sex, obesity, drug consumption during the past month,
and medical or family history of diabetes [18]. All those
who were not taking diabetes medication underwent a 2-
hour oral glucose tolerance test (OGTT) after an over-
night fast. Criteria for control selection were fasting
glucose <6.1 mmol/L and 2 hours plasma glucose
<7.8 mmol/L after OGTT. Diabetes was defined as
fasting glucose 7.0 mmol/L, 2 hours glucose
11.1 mmol/L after OGTT, or use of hypoglycemic
medication. Systolic and diastolic blood pressure was
measured twice in the right arm of the patients who had
been resting for at least 10 minutes in a comfortable
position. Signed informed consent was obtained from all
patients, and the study was approved by the Institutional
Ethics Committee Ilam University of Medical Sciences.
All participants were interviewed to obtain clinical data
and T2DM family histories. Body mass index was
estimated by dividing weight in kilograms by the height
in meters squared. Insulin resistance was assessed from
glucose and insulin concentrations using the homeosta-
sis model assessment of insulin resistance (HOMA-IR)
equation [19].
2.2. Sample preparation
Blood samples were collected from patients and
controls in the morning, after an overnight (12e14 hour)
fasting. Five milliliters of venous blood was withdrawn
from the antecubital vein into Vacutainer tubes (Terumo
GmbH, Eschborn, Germany) containing EDTA as the
anticoagulant. To separate plasma, blood samples were
centrifuged at 3000 rpm for 10 minutes. Supernatant was
used for biochemical experiments, and the buffy coat
and red blood cell pellet were used for DNA extraction.
2.3. Biochemical assays
Serum blood glucose, triglycerides, total cholesterol,
and low-density and high-density lipoprotein cholesterol
(LDL-C and HDL-C) levels were measured by the
standard enzymatic method (Pars Azmon kit, Tehran,
Iran), using the auto analyzer system BT3000 (Bio-
technica, Rome, Italy). Serum concentrations of insulin
were assessed using a specific enzyme-linked immuno-
sorbent assay kit for human insulin according to the
manufacturer’s instructions (Monobind Inc., Lake For-
est, CA, USA).
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Leukocyte genomic DNA was extracted from the
blood specimen using the standard procedure involving
proteinase K (Qiagen, Hilden, Germany) and phenol/
chloroform (Merck, Darmstadt, Germany). The -308 G/
A TNF-a promoter polymorphism was amplified by the
polymerase chain reaction (PCR) method using the
primer pair 50-AGGCAATAGGTTTTGAGGGCCAT-30
(forward) and 50-TCCTCCCTGCTCCGATTC CG-30
(reverse). PCR was performed in a final volume of
25 mL containing 100 ng genomic DNA, 1.5 mmol/L
MgCl2, 0.5 mmol/L of each dNTPs, and 0.5 pmol of
each primer. After an initial denaturation of 2 minutes at
94C, the samples were subjected to 35 cycles at 94C
for 1 minute, 58.5C for 40 seconds, and 72C for 30
seconds, with a final extension of 10 minutes at 72C.
All PCR materials were purchased from the CinnaGen
Company (Tehran, Iran). The 107-bp product was
digested with restriction enzyme NcoI (Fermentas, St.
Leon-Rot, Germany) for 5 hours at 37C followed by
agarose gel electrophoresis. The digested products were
stained with ethidium bromide. A-allele was not cleaved
by NcoI and gave a 107-bp band, and G-allele was
cleaved into two bands 87- and 20-bp.
2.5. Statistical analysis
All statistical analyses were carried out using the
statistical program SPSS (version 19, SPSS Inc., Chi-
cago, IL, USA). Differences in genotype/allele fre-
quencies were compared using the Chi-square test or
Fisher’s exact test where appropriate. One-way analysis
of variance was utilized to compare the clinical features
among groups with different genotypes. Odds ratios and
95% confidence interval were calculated by logisticTable 1. Anthropometrical and biochemical characteristics of s
Characteristics T2DM
Number of individuals (male/female) 1023 (493/
Age (y) 54.98  1.
BMI (kg/m2) 28.8  4.8
WHR 0.94  0.0
FPG (mmol/L) 9.18  2.7
HbA1c (%) 8.13  1.7
TG (mmol/L) 2.07  0.4
TC (mmol/L) 5.13  1.0
HDL-C (mmol/L) 0.93  0.2
LDL-C (mmol/L) 3.89  0.9
SBP (mm Hg) 13.1  1.8
DBP (mm Hg) 8.46  1.3
FPI (mIU/mL) 9.9  3.41
HOMA-IR 3.98  1.7
Data are presented as mean  standard deviation. p values <0.05 are consi
pressure; FPG Z fasting plasma glucose; FPI Z fasting plasma insulin; HbA
HOMA-IR Z homeostasis model assessmenteinsulin resistance; LDL-C Z
TC Z total cholesterol; TG Z triglyceride; WHR Z waist to hip ratio.regression analysis using diabetes as a dependent vari-
able and the genotypes as independent variables.
We used the Pearson goodness-of-fit chi-square (c2)
test to evaluate the deviation from HardyeWeinberg
equilibrium. The Armitage trend test was applied to
assess for the presence of association between different
groups of genotypes. Other genetic models including
dominant, recessive, and multiplicative models were
also considered to analyze single nucleotide poly-
morphism association [20]. The Bonferroni method was
used to correct for multiple comparisons where appli-
cable. A p value <0.05, using two-sided tests, was
considered statistically significant, whereas a value of
corrected p < 0.0167 for genotype analysis was
considered significant after Bonferroni correction.
Baseline quantitative results were expressed as
mean  standard deviation (SD) and compared with the
Student t test; the continuous variables that failed the
normality test were logarithmically transformed prior to
analysis. The variables transformed were triglyceride,
insulin, and HOMA-IR. Statistical differences are based
on analyses of log-transformed data, but means of un-
transformed data are presented in Tables 1 and 3.3. Results
The clinical, anthropometrical, and biochemical
characteristics of the participants are shown in Table 1.
Sex distribution was almost the same in T2DM patients
and controls. The mean of age in patients with T2DM
and the control group was 54.98  11.1 years and
53.3  9.7 years, respectively. All characteristics of the
participants differed significantly between T2DM andtudy groups.
Groups
Control p
530) 1038 (502/536) _
11 53.3  9.7 0.18
6 26.9  4.32 <0.001
7 0.91  0.062 <0.001
5 5.29  0.57 <0.001
2 5.02  0.35 <0.001
7 1.65  0.46 <0.001
6 4.65  1.1 <0.001
5 2.99  0.69 <0.001
4 3.04  0.8 <0.001
5 11.86  1.07 <0.001
1 8.0  0.95 <0.001
7.33  2.08 <0.001
7 1.72  0.5 <0.001
dered as significant. BMI Z body mass index; DBP Z diastolic blood
1c Z hemoglobin A1c; HDL-C Z high-density lipoprotein cholesterol;
low-density lipoprotein cholesterol; SBP Z systolic blood pressure;
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T2DM s had significantly higher values for body mass
index, triglyceride, hemoglobin A1c, glucose, total
cholesterol, waist to hip ratio, LDL-C, HOMA-IR, dia-
stolic and systolic blood pressure and insulin, and lower
levels of HDL-C than normoglycemic control partici-
pants (all p < 0.001).
The genotype distribution and relative allele fre-
quencies of -308 G/A TNF-a promoter polymorphism for
the study patients are shown in Table 2. This variant was in
Hardy-Weinberg equilibrium in T2DM (c2 Z 1.49,
dfZ 1, pZ 0.22) and control patients (c2Z 2.7, dfZ 1,
p Z 0.12). The A-allele frequency of -308 G/A TNF-a
promoter polymorphism was significantly (0.006)
different between case and control groups (16% vs. 8%,
respectively). Genotypes GA and AA were found to be
significantly associated with 2.24- and 3.18-fold increased
risk for T2DM, respectively. In addition, in the dominant
model (GG vs. GA þ AA), the -308 G/A TNF-a poly-
morphism was found to be significantly associated with
T2DM (ORZ 2.34, 95% CIZ 1.88e2.91, pZ 0.001),
but no significant association was detected for the reces-
sive model (GG þ GA vs. AA).
We classified the anthropometric, clinical, and
biochemical characteristics of the study patients ac-
cording to the dominant model for 308 G/A TNF-a
polymorphism (Table 3). As shown in Table 3, patients
with T2DM carrying the GA þ AA genotypes of this
variation had a significantly lower fasting plasma insulin
(GG; 10.13  3.49 vs. GA þ AA; 8.66  2.59 mIU/mL,
p Z 0.03) as compared with those carrying GG geno-
type. No significant difference was found for any of the
clinical and biochemical variables in normoglycemic
individuals carrying GG genotype in comparison with
carriers of GA þ AA genotypes.T
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a.4. Discussion
The candidate gene approach focuses on the associ-
ations between genetic variation within prespecified
genes of interest and phenotypes or disease states based
on a priori knowledge of the gene’s biological func-
tional impact on the trait or disease in question [21,22].
Case-control studies are often used to find the differ-
ences of allele frequency of a candidate gene between
case and control patients [21].
Inflammation has been widely known as an important
feature of T2DM, with high levels of proinflammatory
cytokines, including IL-1, IL-6, and TNF-a. Because
TNF-a can impair insulin signal pathways and lead to b-
cell destruction, increased TNF-a is considered to play a
central role in the development of T2DM [7]. So far,
many studies have focused on the association between
-308G/A TNF-a promoter polymorphism and T2DM, but
the results were still controversial [6,9,16e18,23e25]. In
this study, we examined the association of the mentioned
Table 3. The characteristics of the study subjects according to the dominant model of -308 G/A polymorphism of tumor
necrosis factor-alpha.
Characteristics
Patients with Type 2 diabetes Control patients
GG (737) GA þ AA (301) p GG (871) GA þ AA (152) p
BMI (kg/m2) 29.0  5.09 27.68  3.10 0.19 27.06  4.27 24.51  4.41 0.05
WHR 0.94  0.068 0.92  0.06 0.34 0.90  0.06 0.92  0.11 0.36
FPG (mmol/L) 9.16  2.87 9.25  1.92 0.87 5.28  0.56 5.25  0.67 0.83
HbA1c (%) 8.16  1.78 7.95  1.33 0.56 5.02  0.34 4.92  0.42 0.37
TG (mmol/L) 2.07  0.46 2.06  0.51 0.92 1.64  0.46 1.69  0.40 0.71
TC (mmol/L) 5.08  1.02 5.35  1.23 0.22 4.63  1.10 4.83  0.98 0.56
HDL-C (mmol/L) 0.92  0.24 0.97  0.21 0.28 2.98  0.67 3.15  0.88 0.42
LDL-C (mmol/L) 3.45  0.92 3.70  0.97 0.06 2.92  0.80 3.06  0.73 0.21
SBP (mm Hg) 13.04  1.83 13.35  1.94 0.42 11.88  1.08 11.36  0.81 0.09
DBP (mm Hg) 8.41  1.20 8.68  1.75 0.32 7.99  0.95 8.09  0.83 0.74
FPI (mIU/mL) 10.13  3.49 8.66  2.59 0.03* 7.30  2.09 7.76  1.77 0.47
HOMA-IR 4.06  1.83 3.53  1.26 0.14 1.70  0.50 1.79  0.39 0.58
Data are presented as mean  standard deviation. p values <0.05 are considered as significant. BMI Z body mass index; DBP Z diastolic blood
pressure; FPG Z fasting plasma glucose; FPI Z fasting plasma insulin; HbA1c Z hemoglobin A1c; HDL-C Z high-density lipoprotein cholesterol;
HOMA-IR Z homeostasis model assessmenteinsulin resistance; LDL-C Z low-density lipoprotein cholesterol; SBP Z systolic blood pressure;
TC Z total cholesterol; TG Z triglyceride; WHR Z waist to hip ratio.
98 H. Golshani, et alpolymorphism with T2DM and related metabolic traits
using a caseecontrol method. We selected this variation
due to their previous association with T2DM
[9,10,19,20,26].
In our study, the allelic frequency of the A-allele of
this variant was significantly (0.006) different between
case and control groups (16% vs. 8%). The frequency of
A-allele of this polymorphism differs from 9% in Chi-
nese populations [27], 16% in French and Scandinavian
populations [28,29], 18% in Germans [30], to 24% in
Australians [10]. There are some points should be con-
cerned for the inconsistent results. Hamann et al [31] did
not find any difference in allele frequencies of the
-308 G/A TNF-a polymorphism among patients with
noninsulin-dependent diabetes mellitus and unrelated
controls [31]. In another study, there was not any sig-
nificant difference in the A-allele of this variant between
case and control groups [26]. Kubaszek et al [32] re-
ported, in their study among the Finnish population, that
the A-allele of the -308 G/A TNF-a variation was
associated with twofold higher risk for T2DM, and was
also a predictor for the conversion from impaired
glucose tolerance to T2DM. Also, no significant differ-
ences were identified for allele frequencies between
control patients and patients with components of the
metabolic syndrome [27]. Ethnic differences may attri-
bute to these different results. However, study design or
small sample size or some environmental factors may
affect the results [9,33,34].
Based on our results, the frequencies of genotype GA
show a significant difference between case and control
individuals. A study conducted by Elsaid et al [26]
showed that there was no significant difference in the
genotype frequencies of GA between case and control
groups. In another study, the heterozygous genotype of-308 G/A TNF-a polymorphism presented with greater
frequency in patients with T2DM than in healthy par-
ticipants and it was statistically significant [35]. In our
study, we found a significant difference in the distribu-
tion of AA genotype between the study groups. In
agreement with our results, Heijmans et al [13] reported
that individuals carrying the AA homozygous genotype
(TNF hyperproducer) have a 4.6-times greater risk of
presenting with T2DM than an individual with the GG
homozygous genotype (TNF hypoproducer). However,
our results are in contrast with the results from the
Taiwanese population [25]. We also found that the
dominant model of -308 G/A TNF-a polymorphism be
significantly associated with T2DM. This result was in
accordance with the results from Caucasian and Asian
populations [9].
In our study, patients with T2DM carrying the
GA þ AA genotypes of -308 G/A TNF-a variation had
significantly lower fasting insulin levels, as compared
with the carriers of GG genotype. This result was in
contrast to another study, which found that patients
homozygous for the A allele had higher fasting insulin
levels [10]. Furthermore, no significant differences were
identified between patients with the GG genotype and
those with the mutant allele (GA and AA) for clinical
and biochemical parameters in some previous studies
[27,30]. The reason for the apparent discrepancies be-
tween the studies, including ours, can be attributed to
several factors such as the study design, sample size,
population heterogeneity, and gene-environment in-
teractions [33,34].
In conclusion, this is the first study performed in the
Kurdish ethnic group from West Iran, in which the
significance of -308 G/A TNF-a genetic variation were
investigated in the pathogenesis of T2DM. The findings
Association of TNF-a 308 G/A Polymorphism, Type 2 Diabetes 99of our study revealed that the -308 G/A polymorphism
of TNF-a is associated with the risk of T2DM.Conflicts of interest
The authors declare that they have no conflicts of
interest.
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